Intellia Therapeutics Inc buy Wells Fargo & Company
Start price
08.08.25
/
50%
€9.49
Target price
08.08.26
-
Performance (%)
22.89%
Price
27.02.26
€11.66
Summary
This prediction is currently active. The prediction currently has a performance of 22.89%. This prediction currently runs until 08.08.26. The prediction end date can be changed by Wells_Fargo___Compan at any time. Wells_Fargo___Compan has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Intellia Therapeutics Inc | 8.566% | 8.566% |
| iShares Core DAX® | -0.383% | 1.093% |
| iShares Nasdaq 100 | -0.411% | -1.973% |
| iShares Nikkei 225® | 1.838% | 10.261% |
| iShares S&P 500 | -0.712% | 0.445% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company.
Ratings data for NTLA provided by MarketBeat
Stopped prediction by Wells_Fargo___Compan for Intellia Therapeutics Inc
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€9.50
28.02.25
28.02.25
€48.09
28.02.26
28.02.26
22.74%
27.02.26
27.02.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€10.22
10.01.25
10.01.25
€58.40
10.01.26
10.01.26
-11.94%
11.01.26
11.01.26
Intellia Therapeutics Inc
Start price
Target price
Perf. (%)
€13.35
18.11.24
18.11.24
€66.07
18.11.25
18.11.25
-46.02%
19.11.25
19.11.25